Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants

Journal of Virology

Volumn 79, Issue 14, 2005, Pages 9062-9068

  Bakker, Alexander B H ^a   Marissen, Wilfred E ^a   Kramer, R Arjen ^a   Rice, Amy B ^b   Weldon, William C ^c   Niezgoda, Michael ^c   Hanlon, Cathleen A ^c   Thijsse, Sandra ^a   Backus, Harold H J ^a   De Kruif, John ^a   Dietzschold, Bernhard ^b   Rupprecht, Charles E ^c   Goudsmit, Jaap ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPLOID CELL VACCINE; EPITOPE; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY CR4098; HUMAN MONOCLONAL ANTIBODY CR57; IMOGAM RABIES HT; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; ESCAPE MUTANT; IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; POSTEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; RABIES VIRUS; SYRIAN HAMSTER; VIRUS MUTANT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CRICETINAE; GENOTYPE; GLYCOPROTEINS; IMMUNOGLOBULIN G; MESOCRICETUS; MICE; MUTATION; NEUTRALIZATION TESTS; RABIES; RABIES VIRUS; VIRAL ENVELOPE PROTEINS;

RABIES VIRUS;

EID: 21644487726     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.14.9062-9068.2005     Document Type: Article

References (29)

1. Benmansour, A., H. Leblois, P. Coulon, C. Tuffereau, Y. Gaudin, A. Flamand, and F. Lafay. 1991. Antigenicity of rabies virus glycoprotein. J. Virol. 65:4198-4203.
2. Centers for Disease Control and Prevention. 1999. Mass treatment of humans who drank unpasteurized milk from rabid cows-Massachusetts, 1996-1998. Morb. Mortal. Wkly. Rep. 48:228-229.
3. Centers for Disease Control and Prevention. 1999. Multiple human exposures to a rabid bear cub at a petting zoo and barnwarming-Iowa, August 1999. Morb. Mortal. Wkly. Rep. 48:761.
4. Coulon, P., J. P. Ternaux, A. Flamand, and C. Tuffereau. 1998. An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro. J. Virol. 72:273-278.
5. Diallo, A. 1986. Avirulent mutants of the rabies virus: change in site III of the glycoprotein. Ann. Rech. Vet. 17:3-6. (In French.)
6. Dietzschold, B., M. Gore, P. Casali, Y. Ueki, C. E. Rupprecht, A. L. Notkins, and H. Koprowski. 1990. Biological characterization of human monoclonal antibodies to rabies virus. J. Virol. 64:3087-3090.
7. Dietzschold, B., M. Tollis, M. Lafon, W. H. Wunner, and H. Koprowski. 1987. Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 161:29-36.
8. Dietzschold, B., W. H. Wunner, T. J. Wiktor, A. D. Lopes, M. Lafon, C. L. Smith, and H. Koprowski. 1983. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. USA 80:70-74.
9. Enssle, K., R. Kurrle, R. Kohler, H. Muller, E. J. Kanzy, J. Hilfenhaus, and F. R. Seiler. 1991. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10:547-556.
10. Fallaux, F. J., A. Bout, I. van der Velde, D. J. van den Wollenberg, K. M. Hehir, J. Keegan, C. Auger, S. J. Cramer, H. van Ormondt, A. J. van der Eb, D. Valerio, and R. C. Hoeben. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9:1909-1917.
11. Flamand, A., H. Raux, Y. Gaudin, and R. W. Ruigrok. 1993. Mechanisms of rabies virus neutralization. Virology 194:302-313.
12. Hanlon, C. A., C. A. DeMattos, C. C. DeMattos, M. Niezgoda, D. C. Hooper, H. Koprowski, A. Notkins, and C. E. Rupprecht. 2001. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19:3834-3842.
13. Hanlon, C. A., M. Niezgoda, P. A. Morrill, and C. E. Rupprecht. 2001. The incurable wound revisited: progress in human rabies prevention? Vaccine 19:2273-2279.
14. Hanlon, C. A., M. Niezgoda, and C. E. Rupprecht. 2002. Postexposure prophylaxis for prevention of rabies in dogs. Am. J. Vet. Res. 63:1096-2100.
15. Irie, T., and A. Kawai. 2002. Studies on the different conditions for rabies virus neutralization by monoclonal antibodies #1-46-12 and #7-1-9. J. Gen. Virol. 83:3045-3053.
16. Kankanamge, P. J., T. Irie, K. Mannen, T. S. Tochikura, and A. Kawai. 2003. Mapping of the low pH-sensitive conformational epitope of rabies virus glycoprotein recognized by a monoclonal antibody #1-30-44. Microbiol. Immunol. 47:507-519.
17. Lafon, M., J. Ideler, and W. H. Wunner. 1984. Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies. Dev. Biol. Stand. 57:219-225.
18. Lafon, M., T. J. Wiktor, and R. I. Macfarlan. 1983. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J. Gen. Virol. 64:843-851.
19. Marissen, W. E., R. A. Kramer, A. Rice, W. C. Weldon, M. Niezgoda, M. Faber, J. W. Slootstra, R. H. Meloen, M. Clijsters-van der Horst, T. J. Visser, M. Jongeneelen, S. Thijsse, M. Throsby, J. de Kruif, C. E. Rupprecht, B. Dietzschold, J. Goudsmit, and A. B. H. Bakker. 2005. Novel rabies neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J. Virol. 79:4672-4678.
20. Montano-Hirose, J. A., M. Lafage, P. Weber, H. Badrane, N. Tordo, and M. Lafon. 1993. Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice. Vaccine 11:1259-1266.
21. Prehaud, C., P. Coulon, F. LaFay, C. Thiers, and A. Flamand. 1988. Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J. Virol. 62:1-7.
22. Prosniak, M., M. Faber, C. A. Hanlon, C. E. Rupprecht, D. C. Hooper, and B. Dietzschold. 2003. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J. Infect. Dis. 188:53-56.
23. Rupprecht, C. E., B. Dietzschold, J. H. Cox, and L. G. Schneider. 1989. Oral vaccination of raccoons (Procyon lotor) with an attenuated (SAD-B19) rabies virus vaccine. J. Wildl. Dis. 25:548-554.
24. Schumacher, C. L., B. Dietzschold, H. C. Ertl, H. S. Niu, C. E. Rupprecht, and H. Koprowski. 1989. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J. Clin. Investig. 84:971-975.
25. Seif, I., P. Coulon, P. E. Rollin, and A. Flamand. 1985. Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J. Virol. 53:926-934.
26. Tordo, N. 1996. Characteristics and molecular biology of rabies virus, p. 28-51. In F.-X. Meslin, M. M Kaplan, and H. Koprowski (ed.), Laboratory techniques in rabies, 4th ed. World Health Organization, Geneva, Switzerland.
27. Tuffereau, C., J. Benejean, D. Blondel, B. Kieffer, and A. Flamand. 1998. Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J. 17:7250-7259.
28. Tuffereau, C., H. Leblois, J. Benejean, P. Coulon, F. Lafay, and A. Flamand. 1989. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology 172:206-212.
29. World Health Organization. 2002. Monoclonal antibody cocktail for rabies post exposure treatment: report of a WHO consultation, 23-24 May 2002. World Health Organization document R2-370-15. World Health Organization, Geneva, Switzerland.